Zobrazeno 1 - 10
of 118
pro vyhledávání: ''
Autor:
Ashish Panigrahi, Constantine S. Tam, Piers Blombery, Xiangting Chen, John F. Seymour, Dennis A. Carney, Andrew H. Wei, Thomas E Lew, Mary Ann Anderson, Andrew W. Roberts, Ella R. Thompson, David C. S. Huang, Tamia Nguyen, David Westerman, Michael A. Dengler, Victor S Lin, Sasanka M. Handunnetti, Jerry M. Adams
Publikováno v:
Blood. 139:1198-1207
The BCL2 inhibitor venetoclax has established therapeutic roles in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). As BCL2 is an important determinant of survival of both myeloid progenitor and B cells, we investigated whether cl
Autor:
John C. Byrd, Deborah M. Stephens
Publikováno v:
Blood
Bruton tyrosine kinase inhibitors (BTKi) have significantly changed the treatment landscape for patients with B-cell malignancies, including chronic lymphocytic leukemia, Waldenstrom macroglobulinemia, mantle cell lymphoma, and marginal zone lymphoma
Autor:
Isabelle S. Csete, Ross L. Levine, Qi Gao, Alexander Chan, Andriy Derkach, Maximilian Stahl, Sheng F. Cai, Jinjuan Yao, Tanmay Mishra, Richard Koche, Sophia Yanis, Martin S. Tallman, Aaron D Goldberg, Michael R. Waarts, Raajit K. Rampal, Ahmet Dogan, Robert L. Bowman, Minal Patel, Ying Liu, Wenbin Xiao, Mikhail Roshal, Maria E. Arcila, Jeeyeon Baik, Nicole L. DelGaudio, Christopher Famulare, Yanming Zhang
Publikováno v:
Blood
Plasmacytoid dendritic cells (pDCs) are the principal natural type I interferon–producing dendritic cells. Neoplastic expansion of pDCs and pDC precursors leads to blastic plasmacytoid dendritic cell neoplasm (BPDCN), and clonal expansion of mature
Autor:
Gilad Itchaki, Svitlana Tyekucheva, Shuai Dong, Ignaty Leshchiner, Ishwarya Murali, Dimitri Livitz, Emily M. Thrash, Jasneet Kaur Khalsa, Amy J. Johnson, Gad Getz, Jennifer R. Brown, Stacey M. Fernandes, Siddha Kasar, Aishath S Naeem
Publikováno v:
Blood. 138:44-56
Inhibitors of Bruton tyrosine kinase (BTK) and phosphatidylinositol 3-kinase δ (PI3Kδ) that target the B-cell receptor (BCR) signaling pathway have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Mutations associated with resist
Autor:
Hsin-An Hou, Amy L. Aldrich, Amy F McLemore, Susan Geyer, Eric Padron, Kathy L. McGraw, Abhishek Dhawan, Rami S. Komrokji, Sarah Warren, John L. Cleveland, Kyle J. MacBeth, Steffen Boettcher, Alan F. List, Benjamin L. Ebert, Amy Sullivan, Jeffrey E. Lancet, Erika A. Eksioglu, Manja Meggendorfer, Najla Al Ali, Torsten Haferlach, David A. Sallman
Publikováno v:
Blood. 136:2812-2823
Somatic gene mutations are key determinants of outcome in patients with myelodysplastic syndromes (MDS) and secondary AML (sAML). In particular, patients with TP53 mutations represent a distinct molecular cohort with uniformly poor prognosis. The pre
Autor:
Xose S. Puente, Ana Muntañola, Ander Diaz-Navarro, José I. Martín-Subero, Blanca Espinet, Roser Vilarrasa-Blasi, Guillem Clot, Cristina López, Marta Kulis, Ferran Nadeu, Rafael Valdés-Mas, Vicente Chapaprieta, Marta Aymerich, Dolors Costa, Elias Campo, David Torrents, Sílvia Beà, Jesús Gutiérrez-Abril, Armando López-Guillermo, David Martín-García, Pedro Jares, Ralf Küppers, Eva Giné, Inmaculada Ribera-Cortada, Montserrat Puiggròs, Giancarlo Castellano, Dolors Colomer, Romina Royo, Martí Duran-Ferrer, Alba Navarro, Reiner Siebert
Publikováno v:
Blood. 136:1419-1432
Mantle cell lymphoma (MCL) is a mature B-cell neoplasm initially driven by CCND1 rearrangement with 2 molecular subtypes, conventional MCL (cMCL) and leukemic non-nodal MCL (nnMCL), that differ in their clinicobiological behavior. To identify the gen
Autor:
Sriram Balasubramanian, Quratulain Qureshi, Christopher Rushton, Miguel Alcaide, Nicole Thomas, Krysta M. Coyle, Bruno M. Grande, Prasath Pararajalingam, Barbara Meissner, Joseph M. Connors, Diego Villa, Ryan D. Morin, Constantine S. Tam, Randy D. Gascoyne, David W. Scott, Graham W. Slack, Christian Steidl, Nathalie A. Johnson, Timothy E. Audas, Marco A. Marra, Sarah E. Arthur, Rishu Agarwal, Andrew J. Mungall, Merrill Boyle, Sarah-Jane Dawson, Georg Lenz
Publikováno v:
Blood. 136:572-584
Mantle cell lymphoma (MCL) is an uncommon B-cell non-Hodgkin lymphoma (NHL) that is incurable with standard therapies. The genetic drivers of this cancer have not been firmly established, and the features that contribute to differences in clinical co
Autor:
Vincent-Philippe Lavallée, Marie-Eve Bordeleau, Laura Simon, Geneviève Boucher, Josée Hébert, Chi-Yuan Yao, Jean-François Spinella, Sébastien Lemieux, Guy Sauvageau, Éric Audemard, Isabel Boivin
Publikováno v:
Blood. 135:1882-1886
RUNX1 is mutated in ∼10% of adult acute myeloid leukemia (AML). Although most RUNX1 mutations in this disease are believed to be acquired, they can also be germline. Indeed, germline RUNX1 mutations result in the well-described autosomal-dominant f
Autor:
Mario Cazzola, Alessandro M. Vannucchi, Chiara Paoli, Rossella Manfredini, Paola Guglielmelli, Elisa Rumi, Francesco Mannelli, Annalisa Pacilli, Sara Fiaccabrino, Giada Rotunno, Giada Brogi, Giovanni Barosi, Benedetta Sordi, Francesca Gesullo, Carmela Mannarelli, Ilaria M. Marone
Publikováno v:
Blood. 133:2802-2808
TO THE EDITOR: The discovery of prognostically informative mutations in patients with primary myelofibrosis (PMF)[1][1] prompted the development of mutation-enhanced risk scores.[2][2][⇓][3][⇓][4][⇓][5]-[6][6] Among these mutations, those in AS
Autor:
Mathijs A. Sanders, Sandra Kaiser, Wei Wang, Sarolta Bojtine Kovacs, Lars Bullinger, Bruno Cassinat, Annelieke Zeilemaker, Christoph Koellerer, Peter J. M. Valk, Jonas S. Jutzi, Titiksha Basu, Adil Al Hinai, Jenny Ostendorp, Brigitte Schlegelberger, Heike L. Pahl, Emmanuel Raffoux, Doris Steinemann, Maximilian Pellmann, Konrad Aumann
Publikováno v:
Blood, 133(16), 1766-1777. American Society of Hematology
In acute myeloid leukemia (AML), acquired genetic aberrations carry prognostic implications and guide therapeutic decisions. Clinical algorithms have been improved by the incorporation of novel aberrations. Here, we report the presence and functional